Department of Clinical Pharmacy, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Guangzhou key laboratory of construction and application of new drug screening model systems, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Exp Cell Res. 2018 Mar 15;364(2):208-216. doi: 10.1016/j.yexcr.2018.02.005. Epub 2018 Feb 7.
High expression of tumoral vascular endothelial growth factor C (VEGF-C) is correlated with clinical non-small cell lung cancer (NSCLC) metastasis and patient survival. Nevertheless, the comprehensive mechanisms accounting for VEGF-C-mediated cancer progression remain largely unclear. The present study found that VEGF-C expression was upregulated in various NSCLC cell lines. By utilizing transwell migration assay, we found that both recombinant VEGF-C protein and overexpression of VEGF-C in NSCLC cells (A549 and H441 cell lines) could efficiently enhance RAW264.7 cell (murine macrophages) migration. However, recombinant VEGF-C treatment had no effects on both CD206 (an M2 macrophage marker) expression and M1/M2 cytokine profiles of macrophages. Furthermore, additional treatment of recombinant Flt-4/Fc, the specific VEGFR-3 inhibitor or the specific VEGFR-2 inhibitor significantly suppressed macrophage migration compared with A549-CM (conditioned medium) or H441-CM alone group, confirming that NSCLC cells-derived VEGF-C is sufficient to promote macrophage migration. Interestingly, VEGF-C could stimulate the Src/p38 signaling via VEGFR-2/3 axis in macrophages, and inhibition of Src/p38 signaling obviously reversed the enhancement effect of VEGF-C on macrophage migration. Finally, the functional importance of macrophage infiltration induced by tumoral VEGF-C in promoting metastasis was established in a mouse model. In conclusion, our results highlight a novel function of tumoral VEGF-C that paracrinely induces macrophage recruitment, and resultantly promotes NSCLC cell metastasis. Therefore, VEGF-C/VEGFR-2/3 axis may be a promising microenvironmental target against progression of NSCLC.
肿瘤血管内皮生长因子 C(VEGF-C)的高表达与临床非小细胞肺癌(NSCLC)的转移和患者的生存相关。然而,VEGF-C 介导的癌症进展的全面机制在很大程度上仍不清楚。本研究发现,VEGF-C 在各种 NSCLC 细胞系中表达上调。通过使用 Transwell 迁移实验,我们发现重组 VEGF-C 蛋白和 NSCLC 细胞(A549 和 H441 细胞系)中 VEGF-C 的过表达均能有效地增强 RAW264.7 细胞(小鼠巨噬细胞)的迁移。然而,重组 VEGF-C 处理对巨噬细胞的 CD206(M2 巨噬细胞标志物)表达和 M1/M2 细胞因子谱均没有影响。此外,与 A549-CM(条件培养基)或 H441-CM 单独处理组相比,重组 Flt-4/Fc、特异性 VEGFR-3 抑制剂或特异性 VEGFR-2 抑制剂的额外处理显著抑制了巨噬细胞的迁移,证实了 NSCLC 细胞来源的 VEGF-C 足以促进巨噬细胞迁移。有趣的是,VEGF-C 可以通过 VEGFR-2/3 轴刺激巨噬细胞中的Src/p38 信号通路,而 Src/p38 信号通路的抑制明显逆转了 VEGF-C 对巨噬细胞迁移的增强作用。最后,在小鼠模型中建立了肿瘤 VEGF-C 诱导的巨噬细胞浸润在促进转移中的功能重要性。总之,我们的研究结果强调了肿瘤 VEGF-C 的一个新功能,即旁分泌诱导巨噬细胞募集,并促进 NSCLC 细胞的转移。因此,VEGF-C/VEGFR-2/3 轴可能是一种有前途的针对 NSCLC 进展的微环境靶点。